Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Drugs Ferritin-analogs

 Avirulent herpetic viruses useful as tumoricidal agents and vaccines
The present invention provides a herpetic virus selected from the group consisting of neurotrophic ...


 Attachment enhanced 293 cells
In one aspect, the invention provides improved HEK 293 cells, which cells are 293 cells which have ...


 Method for the production of polypeptides
The above identified purpose is achieved with the method according to the present invention which ...


 Silver halide emulsions with recombinant collagen suitable for photographic application and also the preparation thereof
What is claimed is: 1. A tabular silver halide emulsion wherein the tabular grains account for more ...


 DNA sequences coding for a protein conferring male sterility
Thus, in a first aspect the present invention provides recombinant or isolated Nucleic acid which: ...


 Tumor associated nucleic acids and uses therefor
OF THE INVENTION The examples which follow show the isolation of nucleic acid molecules which code ...


 Mad-related genes in the human
It is an object of the invention to provide a cDNA of the human Smad2 gene. It is another object of ...


 Tumor associated nucleic acids and uses therefor
OF THE INVENTION The examples which follow show the isolation of nucleic acid molecules which code ...


 Computer-aided display for comparative gene expression
The present invention provides innovative systems and methods for visualizing information collected ...


 Polymorphic repeats in human genes
OF PARTICULAR EMBODIMENTS OF THE INVENTION The following descriptions of particular embodiments ...


 Ferritin analogs

Details
Inventors: Monzyk, Bruce F.;
Assignee: Monsanto Company (St. Louis, MO)
Primary Examiner: Page; Thurman K.
Assistant Examiner: Kishore; G. S.
Attorney, Agent or Firm: Kelley; Thomas E., Wachter; Mark F.

Ferritin analogs comprising an apoferritin protein shell and a core substantially devoid of ferrihydrite, e.g. of inorganic composition such as aluminum hydroxide or organic composition such as acetaminophen. The protein shell can be removed from ferritin analog to produce spherules having a substantially monomodal nominal diameter between about 45 and 100 Angstroms.

DETAILED DESCRIPTION Despite the fact that ferritin is extremely selective in accumulating, storing and dispensing iron in living things, I have discovered that the forgoing objectives can be realized by inserting any of a variety of compositions into apoferritin at unexpectedly high purity and concentration to provide ferritin analogs.
Such ferritin analogs comprise a core which is substantially devoid of ferrihydrite, the natural core of ferritin.
For some applications the protein shell of the ferritin analog serves as an advantageous encapsulant for the core material, e.
g.
an organic or inorganic spherule, concentrated solution or other material.
For other applications it may be desirable to remove the protein shell from the ferritin analog to recover the core material as a spherule.
I have discovered that the protein shell can be advantageously removed, e.
g.
by partial or complete pyrolysis in the case of inorganic spherules or by subjecting the ferritin analog to an environment which causes disassembly of the protein shell, e.
g.
low or high pH.
Partial pyrolysis can provide carbon-coated spherules useful, e.
g.
for ceramic applications.
Such spherules have a substantially monomodal, nominal diameter typically in the range of about 4.
5-9 nanometers (45 to 90 Angstroms); such monomodal spherules can be advantageously grown substantially monomodally to even larger spherules or agglomerates of spherules, e.
g.
up to about 20 nanometers (200 Angstroms) or larger, say about 300 nanometers (3000 Angstroms).
I have also surprisingly discovered that monolithic articles prepared from inorganic spherules have unique properties, e.
g.
ceramics can be prepared at substantially lower sintering temperature, with substantially uniform shrinkage and with smaller surface flaws.



Related patents
  Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
What is claimed is: 1. A method for the treatment of a tumor in a mammal, comprising the steps of (i) identifying said tumor as being characterized by overexpression of ...
  Methods for diagnosing early Lyme disease
This invention is based upon the discovery that sera from patients with early Lyme disease contain predominant IgM reactivity to a major 23 kDa protein (p23; also ...
  Tango 243 polypeptides and uses thereof
The present invention is based, at least in part, on the discovery of cDNA molecules which encode the TANGO 228, 240, and 243 proteins, all of which are either wholly ...
  Dermatophagoides proteins and fragments thereof
What is claimed is: 1. An isolated protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:18 and SEQ ID NO:21. 2. A ...
  Tuberculin active proteins and peptides from the cells of tubercle bacilli
What is claimed is: 1. A tuberculin active simple protein from Mycobacterium tuberculosis strain Aoyama B which is characterized by the following amino acid sequence: ##E...
  Therapy for injured muscles
We claim: 1. A method for treating an injured muscle, the method comprising the step of local administration of a therapeutically effective amount of a botulinum toxin ...
  Secreted and transmembrane polypeptides and nucleic acids encoding the same
1. PRO1560 A cDNA clone (DNA19902-1669) has been identified that encodes a novel polypeptide believed to be a novel member of the tetraspan family, designated in the ...
  HIV-specific cytotoxic T-cell responses
OF INVENTION The inventors have found that two nanomer peptides, designated CLP-177 (SEQ ID NO:2) and CLP-72 (SEQ ID NO:8), a hexamer designated CLP-178 (SEQ ID NO:3), ...
  Method of immunomodulatory treatment of insulin dependent diabetes mellitus using mycobacterial cell wall compositions
OF PREFERRED EMBODIMENTS The present invention contemplates a method of immunomodulatory therapy in a mammal said method comprising administering to said mammal an ...
  Susceptibility mutation for breast and ovarian cancer
OF THE PREFERRED EMBODIMENTS The present invention is based on the discovery of a two base pair deletion of nucleotides 3888 and 3889 of the published BRCA1 cDNA ...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved